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Introduction
The increasing worldwide prevalence of nonalcoholic fatty liv-
er disease (NAFLD) is projected to result in a corresponding 
increase in major progressive outcomes, including nonalcohol-
ic steatohepatitis, fibrosis, and hepatocellular cancer (HCC) (1). 
These comorbid complications of NAFLD represent a pressing 
concern, particularly with the emergence of HCC as an increas-
ingly common worldwide cause of cancer-associated mortality 
(2). In addition, because NAFLD progression is associated with 
a range of other comorbidities, including cardiovascular dis-
ease (the leading cause of death among patients with NAFLD; 
ref. 3), there is also an increasing need to understand the role 
of both genetic and environmental modifiers in the etiology 
and progression of those important comorbidities. Among the 
genes identified in NAFLD susceptibility, several have been 
implicated in HCC development, including TM6SF2, PNPLA3, 
MBOAT7, and APOB, suggesting that alterations in genes that 
regulate critical pathways in hepatic lipid compartmentaliza-
tion and/or VLDL secretion may play key roles in both NAFLD 
development and disease progression (4). In relation to NAFLD 
and cardiovascular disease risk, the E167K variant of TM6SF2 
(rs 58542929 C/T) is an important modifier of both blood lipid 
levels and hepatic steatosis, with the rare T variant conferring 
protection against cardiovascular disease because of reduced 
hepatic VLDL secretion but with a consequence of increased 
steatosis and NAFLD development (5).
The association of cardiovascular disease and NAFLD has 
fueled interest in the mechanisms regulating hepatic apolipo-
protein B (APOB) and VLDL production in humans, including 
the possibility that therapeutic targeting of VLDL secretion 
might offer clinical utility as a strategy for lowering plasma lip-
id levels. While some reports suggest that antisense targeting 
of APOB might be feasible without the adverse effects of hepat-
ic steatosis (6), the predominant clinical experience suggests 
that reducing lipid levels by inhibiting VLDL secretion also 
promotes hepatic steatosis (7, 8), although the long-term con-
sequences are still unknown. Other studies have demonstrated 
a role for epigenetic or posttranscriptional gene regulation of 
APOB expression, including a role for Apobec1 complemen-
tation factor (A1CF), an AU-rich RNA-binding protein, identi-
fied in earlier screens for genetic complementation of C-to-U 
The RNA-binding protein Apobec1 complementation factor (A1CF) regulates posttranscriptional ApoB mRNA editing, but 
the range of RNA targets and the long-term effect of altered A1CF expression on liver function are unknown. Here we studied 
hepatocyte-specific A1cf-transgenic (A1cf+/Tg), A1cf+/Tg Apobec1–/–, and A1cf–/– mice fed chow or high-fat/high-fructose diets 
using RNA-Seq, RNA CLIP-Seq, and tissue microarrays from human hepatocellular cancer (HCC). A1cf+/Tg mice exhibited 
increased hepatic proliferation and steatosis, with increased lipogenic gene expression (Mogat1, Mogat2, Cidea, Cd36) 
associated with shifts in polysomal RNA distribution. Aged A1cf+/Tg mice developed spontaneous fibrosis, dysplasia, and HCC, 
and this development was accelerated on a high-fat/high-fructose diet and was independent of Apobec1. RNA-Seq revealed 
increased expression of mRNAs involved in oxidative stress (Gstm3, Gpx3, Cbr3), inflammatory response (Il19, Cxcl14, Tnfα, 
Ly6c), extracellular matrix organization (Mmp2, Col1a1, Col4a1), and proliferation (Kif20a, Mcm2, Mcm4, Mcm6), and a subset 
of mRNAs (including Sox4, Sox9, Cdh1) were identified in RNA CLIP-Seq. Increased A1CF expression in human HCC correlated 
with advanced fibrosis and with reduced survival in a subset with nonalcoholic fatty liver disease. In conclusion, we show 
that hepatic A1CF overexpression selectively alters polysomal distribution and mRNA expression, promoting lipogenic, 
proliferative, and inflammatory pathways leading to HCC.
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to a new role for the RNA-binding protein A1CF in liver pathobi-
ology in both mice and humans.
Results
A1cf+/Tg mice exhibit increased hepatocyte proliferation and a subtle 
shift in VLDL secretion. We generated two A1cf+/Tg founder lines 
(Supplemental Figure 1) with similar expression of the trans-
gene (about 2- to 3-fold above endogenous; Figure 1A), local-
ized predominantly in hepatocyte nuclei (Supplemental Figure 
1A). Young (8- to 14-week-old), chow-fed A1cf+/Tg mice revealed 
elevated liver/body weight ratios and injury reflected by 2-fold 
increased serum alanine aminotransferase (Figure 1B), with no 
change in aspartate aminotransferase. We observed increased 
BrdU-positive hepatocytes in A1cf+/Tg mice (Figure 1B and 
Supplemental Figure 1B) with increased α-fetoprotein (Afp) 
mRNA, consistent with increased proliferation (Supplemental 
Figure 1B). There were more lipid droplets in A1cf+/Tg mice with 
increased hepatic TG content (Figure 1C). Hepatic and serum 
total cholesterol and fatty acids (FAs) were unaltered in A1cf+/Tg 
mice (Supplemental Figure 1C). Fasting serum TGs were com-
parable in both genotypes after a 4-hour fast (Figure 1D), but 
A1cf+/Tg mice showed no increase following a 16-hour fast com-
pared with controls (Figure 1D and Supplemental Figure 1C), 
suggesting subtle impairment of VLDL secretion (16). We also 
RNA editing activity of the cytidine deaminase APOBEC1 (9, 
10). A1CF is widely expressed in both human and mouse tis-
sues, including at high levels in the liver, where it binds a range 
of RNAs, including ApoB and Il6 (11). A1cf-null mice revealed 
distinctive alterations in APOBEC1-dependent C-to-U RNA 
editing, yet these mice revealed no change in hepatic ApoB 
mRNA editing or expression (12, 13). However, neither of those 
studies examined the impact of A1cf deletion on the regula-
tion of hepatic lipid metabolism or the longer-range impact for 
metabolic liver disease. Earlier studies showed that hepatic 
A1CF was upregulated in ob/ob mice and that siRNA knock-
down in hepatocytes impaired VLDL secretion (14). These 
studies collectively raise the possibility that A1CF might exhibit 
both gain- and loss-of-function phenotypes in vivo, consistent 
with findings that an A1CF variant allele is a causal gene for reg-
ulating serum triglyceride (TG) levels in humans (15).
Here we report studies that address these unanswered ques-
tions. We generated liver-specific A1cf-transgenic mice, reveal-
ing a phenotype with spontaneous steatosis, fibrosis, and HCC, 
none of which were observed in A1cf-null mice. We identified 
a range of hepatic A1CF RNA targets and pathways, including 
oxidative stress, inflammation, and extracellular matrix orga-
nization. Finally, we demonstrate that A1CF was overexpressed 
in a subset of patients with HCC. The findings collectively point 
Figure 1. Young (8- to 14-week-old) A1cf+/Tg mice on chow diet exhibit increased proliferation and hepatic steatosis. (A) Western blot of A1cf transgene 
expression in A1cf+/Tg liver using A1CF and FLAG antibodies. (B) Liver/body weight ratio of A1cf+/Tg mice, represented as mean ± SEM, *P < 0.05. Serum 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in A1cf+/Tg mice (11–13 per genotype). Data are shown as mean ± SEM, **P < 0.01. 
Proliferative index expressed as percentage of BrdU-positive hepatocytes (mean ± SEM, n = 6–8), **P < 0.01. (C) H&E- and Oil Red O–stained liver sections 
from A1cf+/Tg mice. Scale bars: 50 μm. Hepatic triglyceride (TG) content (mean ± SEM, 7–12 mice), **P < 0.01. (D) Serum TG after 4- or 16-hour fast (n = 11–15 
animals per group). Data are mean ± SEM, *P < 0.05. (E) Western blot of serum and hepatic APOB. Polysomal distribution of ApoB RNA upon fractionation 
of hepatic cytoplasmic extracts from A1cf+/Tg mice: monosome (fractions 1–6) and polysome (fractions 7–13). Data are representative of 4 separate isola-
tions. Unpaired Student’s t test was used to determine significance between A1cf+/Tg and WT control groups for all experiments.
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hepatic steatosis observed in young A1cf+/Tg mice. Gene ontolo-
gy revealed enrichment in genes involved in lipid biosynthesis 
(Figure 3A), including Cidea, Mogat1, Mogat2, and Cd36 (18–20). 
Quantitative PCR (qPCR) revealed a 30-fold increase in Cidea 
and Mogat1 mRNAs, a 10-fold increase in Mogat2 mRNA, and 
a 2-fold increase in Cd36 mRNA (Figure 3B). We also observed 
increased MOGAT1 and MOGAT2 protein abundance in A1cf+/Tg 
liver (Figure 3C). Analysis of both Cidea and Cd36 RNAs 
revealed a shift into actively translating polysomal fractions 
(Figure 4A), associated with approximately 3-fold increased 
CD36 and (qualitative) CIDEA protein expression (Figure 4B). 
Collectively, these results suggest that hepatic A1CF modulates 
genes involved in hepatic lipogenesis and FA utilization as well 
as hepatic VLDL assembly and secretion, conceivably by alter-
ing polysomal mRNA distribution and translation.
A1cf+/Tg mice develop hepatic fibrosis and spontaneous tumori-
genesis, independent of APOBEC1 expression. Aged (~12-month-
old) A1cf+/Tg mice exhibited increased fibrosis (Figure 5A) and 
fibrogenic mRNA expression, including αSma, Col1a1, and 
Col4a1 (Figure 5A), with increased liver/body weight ratio (Sup-
plemental Figure 3A) and increased serum alanine aminotrans-
ferase (Supplemental Figure 3A). In addition, there were visi-
ble tumors in livers of 12 of 13 aged male A1cf+/Tg mice (Figure 
5B) but none in livers of 7 of 7 aged female A1cf+/Tg mice (data 
not shown). Because A1CF is a component of the C-to-U RNA 
editing machinery and since previous studies have demonstrat-
ed that APOBEC1 overexpression promotes promiscuous RNA 
editing and tumorigenesis (21, 22), we next asked whether there 
was a requirement for APOBEC1 in the tumorigenesis observed 
in A1cf+/Tg mice. We generated a compound line of A1cf+/Tg 
found relatively increased APOB100 in livers of A1cf+/Tg mice, 
along with a shift of ApoB mRNA into actively translating poly-
somal fractions (Figure 1E), further suggesting impaired VLDL 
assembly and secretion in these mice. Fractionation of serum 
indicated a shift into smaller TG- and cholesterol-containing 
VLDL fractions (Figure 2A), with smaller nascent VLDL parti-
cles visualized in A1cf+/Tg mice (Figure 2A). In addition, studies 
in isolated hepatocytes revealed decreased secretion of APOB 
from A1cf+/Tg mice (Figure 2B), even though in vivo VLDL-TG 
secretion rates were comparable in both genotypes after either 
4- or 16-hour fast (Supplemental Figure 1D). These data col-
lectively suggest that hepatic A1cf overexpression results in 
decreased APOB secretion associated with a shift in VLDL 
secretion toward smaller particles.
Prompted by findings showing that A1cf deletion in liv-
er-like hepatoma cells decreased APOB secretion (15), we 
examined hepatic and serum lipid metabolism in A1cf–/– 
mice. However, we found no significant changes in serum or 
hepatic TG or cholesterol content and no change in VLDL secre-
tion or in serum or hepatic APOB content or isoform distribu-
tion in A1cf–/– mice (Supplemental Figure 2, A–D). We generated 
2 independent lines of HepG2 CRISPR-deleted A1CF-null cells 
(17), which revealed an approximately 30% decrease in both 
APOB synthesis and secretion (Supplemental Figure 2, E and 
F). Taken together, these findings suggest that loss of A1CF 
slightly decreases APOB production in HepG2 cells but does 
not alter APOB expression or VLDL secretion in mouse liver.
A1cf+/Tg mice exhibit altered expression of genes promoting FA 
uptake and lipogenesis. We undertook RNA pathway analysis 
to understand the changes associated with the spontaneous 
Figure 2. Young A1cf+/Tg mice show reduced APOB secretion and smaller VLDL particles. (A) Serum lipoprotein profile (n = 4 per group) following a 4-hour fast 
and fractionation by fast protein liquid chromatography. TG and cholesterol levels were biochemically determined. Bottom panel: Electron microscopy of serum 
VLDL particles isolated from pooled serum, 4 hours after Pluronic F-127 injection. Scale bars: 500 nm. Unpaired Student’s t test was used to determine signifi-
cance between groups. Size distribution of VLDL particles is representative of 3 separate evaluations, **P < 0.01. (B) Pulse chase analysis of [35S]-labeled APOB 
synthesis and secretion from primary hepatocytes isolated from A1cf+/Tg mice. Autoradiograph is a representative image of 3 independent experiments.
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Figure 3. Hepatic enrichment in genes 
involved in lipid biosynthesis in A1cf+/Tg 
mice. Expression profile of liver-enriched 
genes in 8- to 14-week-old chow-fed A1cf+/Tg 
mice. (A) Enriched KEGG pathways in differ-
entially expressed genes from A1cf+/Tg livers. 
Heatmap diagram of the more than 2-fold 
differentially expressed genes in A1cf+/Tg mice. 
(B) qPCR validation of differentially upregu-
lated genes involved in lipid biosynthesis (n 
= 6–7 mice per genotype). Data are mean ± 
SEM. Unpaired Student’s t test was used to 
determine significance between genotypes, 
*P < 0.05, **P < 0.01. (C) Western blot anal-
ysis of MOGAT1 and MOGAT2 in livers from 
chow-fed A1cf+/Tg mice. Actin was used as 
loading control. (n = 4–5 mice per genotype.)
Figure 4. Altered expression of genes promoting fatty acid uptake and lipogenesis in A1cf+/Tg mice. (A) Polysomal distribution of Cd36 and Cidea RNAs from 
cytoplasmic extracts from A1cf+/Tg liver. RNA abundance was quantitated by qPCR across monosome (fractions 1–6) and polysome (fractions 7–13). Data are 
representative of 3 separate fractionations. (B) Western blot analysis of CD36 in liver of A1cf+/Tg mice using actin as loading control. Data are mean ± SEM. Sig-
nificance was determined using unpaired Student’s t test, *P < 0.05. Immunohistochemical analysis of CIDEA in liver of A1cf+/Tg mice and littermate controls.
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Ly6c and Ccr2 (Supplemental Figure 4, B and C). We will con-
sider the significance of these findings in a later section, in the 
context of high-fat, high-fructose feeding.
Immunohistochemical analysis revealed heat shock protein 
70 (HSP70), glypican 3 (GPC3), and p62 staining of tumor cells 
in both A1cf+/Tg and A1cf+/Tg Apobec1–/– mice (Figure 6A), with 
scattered inflammatory infiltrates and apoptotic and mitotic 
figures (Figure 6B). Despite the presence of hepatic steato-
sis and scattered inflammatory cells, there was no evidence 
of increased hepatic inflammation, based on lack of change in 
mRNA abundance for inflammation-associated genes in either 
genotype at 12 months (Supplemental Figure 5A). We also 
observed increased expression of β-catenin (both overall and 
nuclear; Figure 6C) as well as its downstream target cyclin D1 
in the livers of aged A1cf+/Tg mice (Figure 6C). These findings are 
relevant since activation of β-catenin is a key event in HCC (25).
Because of the progressive nature of liver tumorigenesis, 
we examined 6-month-old chow-fed male A1cf+/Tg mice, which 
revealed small nodules in 4 of 7 mice. These nodules revealed 
areas of steatosis, inflammation, hepatocyte ballooning, and 
anisonucleosis but were not dysplastic (Supplemental Fig-
ure 5B). We also fed groups of male A1cf+/Tg and A1cf–/– mice a 
Apobec1–/– mice, which, at 12 months, exhibited increased liv-
er/body weight ratio (Supplemental Figure 3A) and increased 
hepatic TG content, without changes in hepatic cholesterol or 
FA content (Supplemental Figure 3B), findings similar to those 
in 12-month-old A1cf+/Tg mice. As expected, these A1cf+/Tg Apo-
bec1–/– mice expressed only APOB100 (Supplemental Figure 3A). 
These aged, male A1cf+/Tg Apobec1–/– mice also developed similar 
numbers of liver nodules when compared with A1cf+/Tg mice (Fig-
ure 5C) and again, similarly to A1cf+/Tg mice, exhibited increased 
hepatocyte proliferation (Supplemental Figure 3C). Histopatho-
logical analysis revealed that 5 of 10 aged A1cf+/Tg Apobec1–/– livers 
exhibited dysplastic nodules, with 1 of 5 exhibiting HCC (Table 
1), suggesting that A1CF-induced tumorigenesis is likely inde-
pendent of both APOBEC1 and RNA editing. In addition, because 
liver-specific A1cf-knockout mice exhibited aberrant alternative 
splicing of ketohexokinase-C RNA (23), a feature associated with 
HCC formation (24), we examined 1-year-old male A1cf–/– mice, 
but observed no spontaneous tumors (0 of 10 mice; Table 1 and 
Supplemental Figure 4A). We observed increased hepatic TG 
content in 12-month-old chow-fed A1cf–/– mice, without changes 
in cholesterol or FA content, and no change in transaminases but 
increased hepatic inflammatory marker mRNA expression for 
Figure 5. Hepatic overexpression of A1CF promotes fibrosis and spontaneous tumorigenesis. (A) Representative images of Sirius red–stained A1cf+/Tg and 
WT livers. Scale bars: 50 μm. Quantitation of Sirius red–stained area expressed as percentage total area (mean ± SEM). Significance was determined using 
unpaired Student’s t test, **P < 0.01 (n = 6). Bottom panel: qPCR evaluation of fibrogenic genes in livers of chow-fed 12-month-old A1cf+/Tg mice. Data are 
mean ± SEM (n = 6 per genotype). Unpaired t test was used to determine significance between 12-month-old groups, *P < 0.05. (B) Gross images of liver from 
A1cf+/Tg and A1cf+/Tg Apobec1–/– mice at 12 months of age fed a low-fat chow diet. (C) Representative images of H&E-stained liver sections from A1cf+/Tg and 
A1cf+/Tg Apobec1–/– mice. The dashed curved lines delineate tumor margin. Scale bars: 100 μm (left) and 50 μm (right). Macroscopic quantitation and size of 
nodules showing total number (top) and maximum size (bottom) of tumors.
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high-fat, high-fructose diet for 6 months in order to examine 
the impact of diet-induced steatosis on hepatic tumorigenesis. 
These findings revealed tumors in 9 of 14 A1cf+/Tg mice (Figure 
7A and Table 2) and increased STAT3 activation with increased 
phospho-STAT3 expression (Figure 7B) along with increased 
expression of a known downstream target, Hif1α mRNA (ref. 26 
and Figure 7C). We also observed immunohistochemical stain-
ing for GPC3 and HSP70 (Figure 7D) and increased expression 
of β-catenin (Figure 7E) in tumor nodules from A1cf+/Tg mice. By 
contrast and consistent with our observations in aged chow-fed 
mice, no tumors were observed in high fat–, high fructose–fed 
A1cf–/– mice (Figure 7A), and there was no change in hepatic 
expression of β-catenin in these mice (Figure 7F). A1cf–/– mice 
exhibited fibrotic injury comparable to that seen in WT6NJ 
controls, with increased hepatic mRNA expression of Col4a1 
and Spp1, along with increased mRNA expression of several 
inflammatory genes (Supplemental Figure 6, A and B), a pat-
tern similar to that described above in 12-month-old chow-fed 
A1cf–/– mice (Supplemental Figure 4C). These findings togeth-
er imply that the hepatic steatosis and inflammatory signaling 
observed in both chow- and high fat–, high fructose–fed A1cf–/– 
mice are insufficient to drive tumor initiation.
Transcriptome-wide analysis of A1cf+/Tg liver and isolat-
ed hepatocytes. The findings to this point demonstrate that 
A1cf+/Tg mice exhibit alterations in mRNAs involved in hepatic 
lipogenic and VLDL assembly pathways, but raise questions 
regarding the mechanisms associated with the fibrogenic and 
tumorigenic phenotypes observed. As an approach to identify 
those pathways, we undertook RNA-Seq and STRING analy-
sis (27) (https://string-db.org/) to examine functional enrich-
ment and protein-protein interaction networks from whole 
liver transcriptomes in young (12-week-old) mice (Figure 8A). 
Those analyses revealed changes in several functional cat-
egories, including cell cycle, extracellular matrix organiza-
tion, TG metabolism, and lipid particle organization as well 
as oxidative stress (Figure 8A). qPCR validated upregulation 
of several target mRNAs involved in these pathways (Figure 
8B). The mRNA changes in regard to cell cycle and extracellu-
lar matrix organization extend findings illustrated above show-
ing increased proliferation and fibrogenesis in A1cf+/Tg mice. 
We pursued the findings implicating altered oxidative stress in 
A1cf+/Tg mice and found that total glutathione levels were signifi-
cantly elevated in A1cf+/Tg liver (Supplemental Figure 7A), with 
no change in reduced or oxidized glutathione and no change in 
mRNAs involved in glutathione synthesis (Supplemental Figure 
7A). We also found no evidence for increased endoplasmic retic-
ulum stress as evidenced by mRNA abundance of Chop, Ire1a, 
Xbp1, Grp78, and Atf4 (Supplemental Figure 7B).
To further examine the range of potential A1CF mRNA tar-
gets, we undertook sequencing of RNA isolated by crosslinking 
immunoprecipitation (RNA CLIP-seq) of RBP-RNA complexes 
(28) on isolated hepatocytes from A1cf+/Tg mice (Supplemental 
Figure 7C) and identified 245 RNAs that copurified with FLAG-
tagged A1CF (here designated direct A1CF targets). Overlapping 
these direct A1CF RNA targets with mRNAs that were significant-
ly differentially expressed in our RNA-Seq studies, we identified 
4 A1CF RNA targets (Sox4, Sparcl1, Smad9, and Dlgap1) (Figure 
9). qPCR revealed 1.5-fold and 2-fold upregulation of Sox4 and 
Sparcl1 mRNAs, respectively, with 2-fold and 10-fold downreg-
ulation of Smad9 and Dlgap1 mRNAs, respectively (Figure 9). 
These mRNAs revealed a trend toward the inverse patterns in 
A1cf–/– liver (Supplemental Figure 7D). SOX4 overexpression in 
liver was shown to stabilize β-catenin and increase cell prolifer-
ation, promoting steatosis and HCC progression (29–32), while 
SPARCL1 overexpression was correlated with tumor angiogene-
sis in HCC (33, 34). Since SMAD9 inhibits bone morphogenetic 
protein (BMP) signaling (34), we asked whether the decreased 
expression of Smad9 in A1cf+/Tg liver was accompanied by chang-
es in Bmp7 mRNA. qPCR revealed a 2-fold increase in A1cf+/Tg liv-
er (Supplemental Figure 7E), findings consistent with the fibro-
genic phenotype observed in A1cf+/Tg mice. These findings, taken 
together, support the notion that mRNAs identified through 
RNA CLIP are likely direct A1CF targets with a plausible role in 
the phenotypes observed. Among the differentially expressed 
RNAs, we also observed increased abundance of several organo-
genic mRNAs (Sox9, Gpc1, Tmprss4) in A1cf+/Tg mice (Supplemen-
tal Figure 7F). Among the features of interest in these mRNAs, 
the presence of an AU-rich 3′-UTR in Sox9 mRNA led us to ask 
whether Sox9 mRNA could represent a target for A1CF, since 
earlier work showed that A1CF is an AU-rich RNA-binding pro-
tein (11). Here we show that Sox9 RNA was immunoprecipitable 
from liver extracts and demonstrated a shift into actively trans-
lating polysomal RNA fractions (Supplemental Figure 7F).
We also undertook transcriptome profiling in isolated 
hepatocytes, revealing 391 upregulated and 574 downregulat-
ed RNAs (Figure 10A). Cd36 mRNA was approximately 4-fold 
upregulated (compare Figure 10A with Figure 3B for whole 
liver), again supporting the conclusion that hepatocyte Cd36 
expression is regulated in response to A1CF overexpression. 
We aligned A1CF RNA targets identified by RNA CLIP with 





No. of animals 7 13 10 7 10
No lesion 7 1 0 7 10
Nondysplastic lesions 0 1 5 0 0
Dysplastic lesions 0 7 4 0 0
HCC 0 4 1 0 0
Table 2. Pathological analysis of livers of 6-month-old A1cf+/Tg 
mice fed a trans-fat/fructose diet
WT A1cf+/Tg WT6NJ A1cf–/–
Animals 8 14 9 12
No lesion 8 5 9 12
Nondysplastic lesions 0 2 0 0
Dysplastic lesions 0 7 0 0
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differentially expressed RNAs in A1cf+/Tg hepatocytes and val-
idated differential expression of 2 mRNAs, Dram1 and Phlda2, 
which showed 2- to 2.5-fold higher levels in A1cf+/Tg hepatocytes 
(Figure 10B). Gene Ontology analysis revealed enrichment of 
pathways related to inflammatory response, supporting the 
phenotype observed in A1cf+/Tg liver (Figure 11A) and consis-
tent with a predicted increase in production of proinflammato-
ry cytokines and chemokines (35), including IL19, Cxcl14, and 
TNFα mRNAs, which were 5- to 12-fold upregulated in A1cf+/Tg 
hepatocytes (Figure 11A). We also analyzed markers of inflam-
mation in whole liver from A1cf+/Tg mice and observed a signifi-
cant increase in mRNAs encoding proinflammatory chemokines 
including CCR2 and CXCL14 that likely contribute to inflamma-
tion, as shown by elevated expression of Ly6c and Tnfα mRNAs 
(Figure 11A). In addition, we examined expression of mRNAs 
encoding tumor suppressor genes (TSGs) and oncogenes (Figure 
11B), revealing 49 TSG mRNAs and 2 oncogene mRNAs among 
the differentially expressed genes from the RNA-Seq analysis. Of 
the 49 TSG mRNAs, 26 clustered in functional categories includ-
ing transcriptional regulation, cell cycle, and protein phosphory-
lation, supporting the phenotype observed in A1cf+/Tg. Among the 
26 TSG mRNAs, 7 showed more than 3-fold alteration by RNA-
Seq, of which 4 TSG mRNAs (Pbrm1, Rb1, Sall2, and Cdh24), val-
idated by qPCR, were significantly downregulated (Figure 11B), 
while 2 oncogenes (Jak3, Klf4) exhibited increased mRNA abun-
dance in A1cf+/Tg liver (Figure 11B).
Whole liver transcriptome analysis in aged A1cf+/Tg liver. The 
data presented above suggest that A1CF overexpression pro-
motes steatosis and hepatocyte proliferation as well as activat-
ing inflammatory and fibrogenic pathways in both whole liver 
and isolated hepatocytes from young mice. In order to under-
stand the tumorigenic pathways in older mice, we next profiled 
mRNAs in aged (12-month-old) A1cf+/Tg liver, which revealed 
1505 differentially expressed RNAs (Figure 12A). Gene Ontol-
ogy and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
analysis revealed enrichment in genes related to extracellular 
matrix organization (Figure 12B). We aligned differentially 
expressed RNAs with RNA CLIP A1CF targets and identified 6 
A1CF RNA targets: 4 with increased abundance (Spag5, Phlda2, 
Abcc12, and Cdh1) and 2 with decreased abundance (Dmrta1 and 
Irx1) in A1cf+/Tg livers (Figure 12C and Figure 13). We attempted 
to assign a definitive role for A1CF in the regulation of these 
RNAs by examining hepatic mRNA expression in aged A1cf–/– 
mice, reasoning that mRNAs that were increased in A1cf+/Tg 
livers would be correspondingly reduced in the livers of A1cf–/– 
mice. Of the 6 RNAs identified above, only E-cadherin 1 (Cdh1) 
met the criteria for a gain-of-function/loss-of-function effect 
(i.e., upregulated in A1cf+/Tg and downregulated in age-matched 
Figure 6. Increased expression of HCC markers in 12-month-old A1cf+/Tg mice. (A) Representative images of HSP70 and p62 expression in HCC from 
12-month-old A1cf+/Tg mice. Representative images of hepatic GPC3 in 12-month-old A1cf+/Tg and A1cf+/Tg Apobec1–/– mice. Arrowheads indicate clusters 
of GPC3-positive cells. (B) Representative H&E images of pathological features identified in 12-month-old A1cf+/Tg liver. Left panel: Arrow indicates focal 
inflammation. Arrowheads indicate apoptotic cells. Right panel: Arrowhead indicates mitotic body. (C) Immunohistochemical staining of 12-month-old 
A1cf+/Tg livers with β-catenin antibody. Expression of β-catenin in liver tissue from A1cf+/Tg and littermate controls evaluated by Western blot and compared 
with actin. Representative images of cyclin D1 in liver from 12-month-old A1cf+/Tg mice. All panels, scale bars: 50 μm.
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were differentially expressed in 12-month-old A1cf+/Tg mouse 
liver were also associated with aberrant expression of A1CF in 
human HCC. Of the 6 RNAs, Spag5 and Cdh1 mRNAs showed 
a significant positive co-occurrence with A1CF (Supplemental 
Figure 9A). Alterations in A1CF were observed in 9% of 360 
patients with HCC, including increased gene copy number 
and increased mRNA expression in a subset as well as reduced 
A1CF expression in another subset, the latter reflecting either 
decreased mRNA or mutational alteration (Supplemental Figure 
9A). These findings hint at the possibility that A1CF expression 
might be altered in patients with HCC.
To resolve that possibility, we examined immunohistochem-
ical expression of A1CF in normal control subjects, cirrhotic 
patients, and patients with HCC. We observed homogeneous 
nuclear A1CF staining in control subjects (Figure 14A, top), with 
heterogeneous staining in cirrhotic nodules as well as in HCC 
with increased nuclear expression at the edge of the invasive 
front of the tumor (Figure 14A, bottom, arrowheads). We also 
performed immunohistochemical analysis of A1CF expres-
sion in a tissue microarray of human HCC samples generated 
at Mayo Clinic, Rochester, Minnesota (clinical data included 
in Supplemental Table 2). We categorized A1CF staining into 4 
A1cf–/– liver) (Figure 13). Abcc12 mRNA was 5-fold upregulat-
ed in A1cf+/Tg liver, recapitulating findings showing increased 
expression in breast cancer (36), and loss of A1CF attenuated 
this increase in mRNA expression (Figure 13). The remaining 
4 RNAs (Spag5, Phlda2, Dmrta1, Irx1) were unchanged in WT 
and A1cf–/– liver (Figure 13 and Supplemental Figure 8). We 
examined features of the 12 mRNAs identified through RNA 
CLIP-Seq as possible A1CF targets, focusing on the 3′-UTR 
(Supplemental Table 1). The majority of these mRNAs (11 of 12) 
were enriched in AU sequences, containing at least 1 AUUUA 
motif or stretches (5 or 6 repeats) of poly(U) elements (Supple-
mental Table 1). These sequence and context preferences are 
consistent with findings from earlier studies (37). Only 1 mRNA 
(Abcc12) contained none of these features and contained less 
than 50% AU content (Supplemental Table 1).
A role for A1CF in human HCC. Genome-wide associa-
tion studies implicate A1CF in regulating hepatic lipid metab-
olism and plasma TG levels (15). Because genetic pathways in 
hepatic lipid metabolism modulate HCC risk in patients with 
NAFLD (38), we took advantage of The Cancer Genome Atlas 
(TCGA) and observed that 6 A1CF RNA targets (Spag5, Abcc12, 
Phlda2, Cdh1, Dmrta1, and Irx1; Supplemental Figure 9A) that 
Figure 7. Accelerated hepatic tumorigenesis in A1cf+/Tg mice fed a trans-fat/fructose diet. (A) Top: Gross images of liver from A1cf+/Tg and A1cf–/– mice fed 
a trans-fat/fructose diet for 6 months. Bottom: H&E staining revealing fat accumulation in all genotypes but dysplastic nodules (dashed area) only in 
A1cf+/Tg liver. Scale bars: 100 μm. (B) Western blot analysis of STAT3 activation/phosphorylation at Tyr 705. p-STAT3 was normalized to total STAT3 (n = 7 
A1cf+/Tg and 4 WT). Unpaired Student’s t test was used to determine significance between groups, *P < 0.05. (C) Expression of STAT3 downstream target, 
Hif1α RNA, by qPCR. Data are mean ± SEM (n = 7 A1cf+/Tg and 4 WT), **P < 0.01 determined by unpaired Student’s t test. (D) Representative images of 
GPC3- and HSP70-stained sections from A1cf+/Tg mice. Distinct nodules are delineated by dashed curved lines. GPC3 staining shows rare cells staining with 
cytoplasmic positivity within the nodule (arrowheads). Positive HSP70 staining in liver nodule, supporting neoplastic progression. Scale bars: 50 μm. (E 
and F) Expression of β-catenin in liver from 7 A1cf+/Tg and 4 WT mice (E) and 5 A1cf–/– mice and 5 aged-matched WT6NJ mice (F). Expression of β-catenin 
normalized to actin is shown as β-catenin/actin ratio. Significance was determined using unpaired Student’s t test, *P < 0.05.
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after adjustment for recurrence and time to first recurrence in 
the subgroup with NAFLD (Supplemental Table 5). We also con-
firmed a significant, independent association of mRNA expres-
sion of A1CF with SPAG5 and with CDH1 in a second cohort of 
patient samples (Supplemental Table 6) of normal and cirrhotic 
liver (Supplemental Figure 9B), suggesting that the associations 
demonstrated in mice overexpressing A1cf may also be relevant 
to conditions (e.g., cirrhosis) that predispose to HCC in humans.
Discussion
Here we show that transgenic overexpression of the RNA-bind-
ing protein A1CF in mouse liver produces a gain-of-function 
phenotype that includes steatosis, increased proliferation, 
inflammation, fibrosis, and spontaneous tumorigenesis. As an 
overarching model (Figure 15), we show that A1CF overexpres-
sion alters hepatic APOB secretion and shifts VLDL production 
into smaller particles, which, along with upregulation of mRNAs 
including lipogenic genes and Cd36, promotes the develop-
ment of hepatic steatosis. In addition, upregulation of mRNAs 
involved in oxidative stress, inflammation, and extracellular 
groups based on average sample pixel intensity per high-power 
field, in both tumor and uninvolved tissue (Figure 14B and Table 
3). A high level of A1CF staining correlated with advanced (F3/4) 
fibrosis in both uninvolved and tumor tissue from the entire 
cohort (Figure 14C) and was also correlated with higher levels 
of α-fetoprotein levels (Figure 14D). We used multivariable Cox 
proportional hazard modeling to show that A1CF staining inten-
sity in the uninvolved tissue was predictive of overall survival, 
with worst survival associated with highest levels of A1CF 
expression. This implied prognostic role of increased A1CF 
staining intensity was independent of TNM stage, tumor num-
ber, and other putative prognostic factors included in the final 
model (Supplemental Table 3). Among a subgroup of 19 HCC 
patients in whom NAFLD was a potential underlying etiology 
(Methods and Supplemental Table 4), the adverse prognostic 
role of increased A1CF staining intensity was further substan-
tiated with a progressive decrease in overall survival apparent 
in patients with increasing levels of A1CF expression (Figure 
14E). Furthermore, using proportional hazard modeling, we 
found that A1CF expression remained predictive of survival 
Figure 8. Differentially expressed genes in livers from young 
A1cf+/Tg mice. (A) Heatmap of the 556 differentially expressed 
genes. STRING analysis of the differentially expressed genes 
showing enriched pathways. (B) qPCR validation of gene 
clusters involved in extracellular matrix organization (red), 
cell cycle (blue), and oxidative stress (green). Data are mean ± 
SEM (n = 6–8), *P < 0.05, **P < 0.01 (unpaired t test).
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matrix organization in A1cf+/Tg mice promotes the development 
of hepatic fibrosis. The convergence of these steatotic and fibro-
genic pathways, together with upregulation of proliferative 
and organogenic mRNAs and decreased expression of tumor 
suppressor mRNAs, promotes spontaneous tumorigenesis and 
HCC (Figure 15). Several elements of our findings and this pro-
posed model merit further discussion.
A1CF is a widely expressed RNA-binding protein identi-
fied in connection with ApoB RNA binding and assembly of a 
functional C-to-U RNA editing complex with APOBEC1 (9, 10). 
However, A1cf deletion produced no effect on ApoB RNA editing 
(12) and variably impacted C-to-U RNA editing of other mRNAs 
(13). More recently, genome-wide association studies implicat-
ed variants in A1CF with specific metabolic traits, including reg-
ulation of plasma TG levels (15, 39). Accordingly, among the pri-
mary objectives of this study was to examine the impact of gain 
and loss of function of A1CF alleles on hepatic RNAs and in par-
ticular the impact on VLDL assembly and secretion. Findings 
demonstrating that CRISPR-mediated A1CF deletion in human 
hepatoma cells greatly decreased APOB secretion (15) led us 
to predict that VLDL production and fasting plasma TG levels 
would be correspondingly reduced in A1cf+/Tg mice and elevated 
in A1cf–/– mice. However, these predictions were only partially 
confirmed. We found a modest decrease in APOB secretion and 
a shift to smaller VLDL particles in A1cf+/Tg mice. However, there 
were no alterations in hepatic TG or VLDL secretion or in APOB 
production in A1cf–/– mice and only a subtle (~30%) decrease in 
APOB secretion from 2 independent A1CF-null HepG2 cells. 
Our transcriptomic surveys further revealed a panel of hepat-
ic mRNAs whose expression was upregulated in A1cf+/Tg mice, 
including Cidea, Mogat1, Mogat2, and Cd36, via mechanisms 
that include shifts into actively translating polysome fractions 
and increased protein expression. A function for A1CF in trans-
porting mRNAs toward actively translating polysomes is consis-
tent with its known nuclear/cytoplasmic shuttling activity in cell 
culture models (14, 40) and with its dynamic pattern of altered 
distribution under metabolic stress (23).
We further observed that aged A1cf+/Tg mice developed 
advanced fibrosis and that male mice developed spontaneous 
liver tumors at high penetrance, even while consuming a chow 
diet. The tumorigenic phenotype was accelerated when male 
mice were fed a high-fat, high-fructose diet, and these mice 
exhibited hepatic STAT3 activation along with downstream 
effects including upregulation of Hif1α mRNA, consistent with 
prior studies linking experimental obesity-associated nonal-
coholic steatohepatitis to advanced features including devel-
opment of HCC (41). These tumors exhibited features asso-
ciated with human HCC, including immunohistochemical 
staining for GPC3 and HSP70, enhanced β-catenin expression, 
and increased expression of cyclin D1. Certain features of the 
temporal progression from steatosis to fibrosis raise the ques-
tion of whether the development of HCC in A1cf+/Tg mice occurs 
as a consequence of — or independently from — fibrogenic and 
inflammatory signaling. The demonstration that A1cf+/Tg mice 
fed high-fat, high-fructose diets exhibit enhanced steatosis and 
inflammatory signaling (augmented STAT3 activation; Figure 
7, A and B) along with dysplastic nodules suggests that the pro-
gressive development of HCC is likely driven by steatotic injury 
and fibrogenic signaling. On the other hand, our findings that 
WT and A1cf–/– mice also develop steatosis, fibrosis, and inflam-
mation when fed high-fat, high-fructose diets, yet mice of nei-
ther genotype develop tumors at 6 months (in contrast to A1cf+/Tg 
mice), suggest that the presence of steatosis and fibrosis alone is 
insufficient to promote HCC.
As a step toward identifying relevant signaling pathways, 
we undertook RNA-Seq from livers of A1cf+/Tg mice at various 
ages and aligned some of the differentially expressed mRNAs 
with RNA CLIP-Seq from isolated hepatocytes. We identified 
12 mRNAs through RNA CLIP-Seq and discovered several 
shared sequence motifs within the 3′-UTR of these mRNAs, 
including the overall AU content, the presence and multiplicity 
of AUUUA motifs, and the presence and multiplicity of poly(U) 
stretches. The preferences for AU and poly(U) motifs are con-
sistent with recent work (37), and these preferences are shared 
by other RNA-binding proteins, including RBM47 and mem-
bers of the hnRNP family (hnRNPH1/2), both of which have 
been shown to interact with A1CF in posttranscriptional regu-
lation (13, 23). Among the RNA CLIP targets, Cdh1 and Spag5 
both have plausible roles in the pathogenesis of HCC. Germ-
line or somatic (loss-of-function) mutations in CDH1 are well 
recognized in a range of cancers, including HCC (42, 43), but 
CDH1 mRNA has also been shown to be upregulated in 40% of 
Figure 9. Schematic representation of differentially expressed genes in young A1cf+/Tg mice in relation to A1CF RNA CLIP targets. Two A1CF RNA targets 
(Sox4 and Sparcl1) are upregulated (red) and 2 (Smad9 and Dlgap1) are downregulated (blue) in A1cf+/Tg liver. Expression of these 4 targets was validated by 
qPCR (n = 7–8) and is shown as mean ± SEM, *P < 0.05, **P < 0.01 (unpaired t test).
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patients with HCC (44), with findings demonstrating selective 
nuclear retention of CDH1 mRNA in some patients (45). These 
latter findings raise the question of whether nucleocytoplasmic 
shuttling activity of A1CF (40) plays a role in compartmentaliz-
ing specific cargo RNAs in tumorigenesis. Another A1CF target, 
SPAG5, was upregulated (mRNA and protein) in HCC and asso-
ciated with poor survival (46). Furthermore, expression of both 
CDH1 and SPAG5 RNA was highly correlated with A1CF RNA in 
patients with cirrhosis (Supplemental Figure 9B). Yet another 
A1CF target, Sox9 mRNA, which was immunoprecipitated from 
hepatocytes from A1cf+/Tg mice, was identified as a hepatic stem 
cell marker in HCC with SOX9 overexpression in patients cor-
relating with reduced overall survival (47).
As for other RNA targets, A1CF likely interacts with RBM47 
in the context of C-to-U RNA editing of ApoB mRNA and mod-
ifies editing activity of the RNA deaminase APOBEC1 on a 
variety of substrates in mouse liver and intestine (13). A1CF com-
petes with hnRNPH1/2 by binding at the 5′ splice site of exon 
Figure 10. Differentially expressed genes in primary hepatocytes from 
young A1cf+/Tg mice in relation to A1CF RNA CLIP targets. (A) Heatmap of 
966 differentially altered genes in primary hepatocytes from A1cf+/Tg mice. 
Upregulation of Cd36 RNA in A1cf+/Tg hepatocytes represented as mean ± 
SEM (n = 6), **P < 0.01 (unpaired t test). (B) Venn diagram showing two 
A1CF RNA CLIP targets (Dram1 and Phlda2) upregulated in A1cf+/Tg hepato-
cytes with mRNA expression, validated by qPCR, shown as mean ± SEM  
(n = 6), *P < 0.05 (unpaired t test).
3C in ketohexokinase mRNA and regulates alternative splicing 
(23). However, we failed to observe spontaneous liver tumors in 
aged, male A1cf–/– mice, in which this alternative splicing event 
would be predicted to increase expression of ketohexokinase 
mRNA with the A isoform, a shift in isoform distribution that 
was shown in other work to promote growth of hepatoma cells 
in nude mice (24). An additional caveat is warranted in the 
interpretation of the temporal shifts in hepatic mRNA expres-
sion noted in A1cf+/Tg mice since those changes likely reflect both 
altered cellular expression and cellular composition. Resolution 
of these possibilities will require study of the cellular composi-
tion and transcriptomic profiles at critical developmental stages.
While we confirmed the same pattern of nuclear A1CF 
staining in human hepatocytes and mouse liver (48), we also 
observed heterogeneity in A1CF expression in cirrhosis and 
HCC with variability in regenerating nodules and tumors. We 
found that increased levels of staining were associated with 
more advanced stages of fibrosis as well as other parameters 
of advanced liver disease (Child-Pugh score and MELD score) 
(Supplemental Table 2). In HCC patients in whom NAFLD was 
an underlying etiology, high levels of A1CF staining were pre-
dictive of reduced overall survival. These observations must 
be interpreted with caution, however. First, this cohort of 
HCC contained only 19 subjects (14%) with NAFLD, and our 
study was not powered to draw conclusions regarding specif-
ic HCC etiology. However, the overall prevalence of NAFLD 
underlying HCC is very similar to that in previous retrospec-
tive cohorts reported from the Mayo Clinic (49). Second, while 
fibrosis stage is an important predictor of all-cause mortality in 
NAFLD patients (50), it is unclear whether A1CF expression is 
associated with compensated cirrhosis and/or bridging fibrosis. 
This reservation is relevant also to our observations that A1CF 
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Teco Diagnostics). Serum and hepatic triglycerides (TGs), cholesterol, 
and nonesterified fatty acid levels were measured using kits (L-Type 
Triglyceride M, 998-02891/998-02892; Cholesterol E, 996-02611; 
and HR Series NEFA-HR(2) 991-34793/999-35193, respectively, all 
from FUJIFILM Wako Diagnostics). Serum was fractionated on tan-
dem Superose 6 columns (Pharmacia FPLC). Liver glutathione was 
evaluated following manufacturer’s protocol (Cayman Chemical).
VLDL secretion. Following a 4- or 16-hour fast, mice were weighed 
and injected with Pluronic F-127 (1 mg/g; Invitrogen) and serum TG 
determined from blood collected 1, 2, and 4 hours after injection.
Electron microscopy. Pooled serum from 2–4 mice was collected 
after Pluronic F-127 injection and VLDL particles separated by ultra-
centrifugation for negative staining electron microscopy.
Histology and immunohistochemistry. For mouse studies, BrdU-pos-
itive hepatocytes were quantitated in each section. Eight to ten fields 
per section, each section containing 4–6 pieces of liver from multiple 
lobes, were analyzed. Fibrosis was assessed by Sirius red staining. 
Using Nuance multispectral imaging software, a spectral library was 
created to analyze a complete experimental group. Liver sections (4 
μm) were stained with anti-A1CF, anti-FLAG, anti-CIDEA, anti–β-cat-
enin, anti-HSP70, anti-GPC3, anti-p62, and anti–cyclin D1. Dilutions 
and origins of each antibody are given in Supplemental Table 7. His-
tological survey was performed by a pathologist blinded to the exper-
imental groups. Liver nodules were counted and classified into dys-
plastic nodules and HCC. The background liver was evaluated for the 
presence of steatosis, inflammation, ballooning, and anisonucleosis. 
For human samples, tissue microarray slides were scanned using a 
Nuance FX multispectral imaging system (CRi, Cambridge Research 
staining is within hepatocytes, suggesting the possibility that 
steatotic hepatocytes release factors that promote fibrogen-
ic and/or inflammatory signaling (51). Third, our conclusions 
regarding A1CF expression in those samples reflect immuno-
histochemical staining intensity, which is at best semiquanti-
tative. Future studies will be required to obtain a more granular 
understanding of A1CF protein distribution and expression in 
relation to the candidate mRNAs implicated and to examine the 
role of RNA trafficking, polysome distribution, and translation 
of those candidate target genes.
Methods
Animals. A1cf–/– and Apobec1–/– mice were on a background of 
C57BL/6NJ or C57BL/6J, respectively (13, 52). For high-fat diet stud-
ies, mice were fed a high–trans-fat, high-fructose diet (TD.06303, 
Envigo) for 6 months. Unless noted otherwise, mice were fasted for 4 
hours and injected with 100 mg/kg of BrdU (Sigma-Aldrich) 2 hours 
before study. Littermate controls were used in all experiments.
Generation of A1cf-transgenic mice. The FLAG-A1cf transgene 
was generated by amplification of A1CF from human cDNA using a 
5′ primer containing FLAG sequence and a KpnI site and a 3′ primer 
containing an XhoI site and cloned into the pLiv7 vector (53). Of 5 
founders, 2 were selected with comparable levels (about 2- to 3-fold) 
of transgene expression for the baseline characterization and original 
description of spontaneous tumorigenesis.
Liver and serum biochemical assessments. Serum levels of alanine 
aminotransferase and aspartate aminotransferase were measured with 
kits (ALT [SGPT], A526-120, and AST [SGOT], A559-150, respectively, 
Figure 11. A1cf+/Tg primary hepatocytes show enrichment in inflammatory response pathways. (A) Gene Ontology analysis showing functional pathways overrep-
resented (red) and underrepresented (blue) in A1cf+/Tg hepatocytes. Relative expression of genes involved in inflammatory response examined by qPCR, in both 
isolated hepatocytes and whole liver (5–8 per genotype). Data are mean ± SEM, *P < 0.05, **P < 0.01 (unpaired t test). (B) Venn diagram representing comparative 
analysis between genes with differentially altered expression in A1cf+/Tg hepatocytes and Tumor Suppressor Gene (TSG) and Oncogene databases. qPCR validation 
of a subset of TSG and Oncogene RNAs from 4–5 independent hepatocyte isolations per genotype. Data are mean ± SEM, *P < 0.05, **P < 0.01 (unpaired t test).
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oligo-dT selection, cDNA library preparation, and whole transcrip-
tome sequencing by Illumina HiSeq2000 as previously described (55).
Gene expression analysis by qPCR. Total RNA was treated with 
DNase and subjected to cDNA synthesis using a High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems). qPCR was 
performed in triplicate. RNA levels were expressed as fold changes 
after normalization to Gapdh RNA. Sequences of primers used for 
qPCR are listed in Supplemental Table 8.
Polysome isolation. Livers were washed in ice-cold PBS supple-
mented with 0.1 mg/mL cycloheximide (Sigma-Aldrich) and minced 
in lysis buffer (25 mM Tris-HCl [pH 7.5], 250 mM NaCl, 5 mM MgCl2, 
0.5 mM PMSF, 0.2 mg/mL heparin [Sigma-Aldrich], 5 mM DTT, 20 U/
mL RNasin [Promega], 0.1 mg/mL cycloheximide, 1% Triton X-100, 
1× protease inhibitor). Homogenized minced livers were resolved 
through a 10%–50% sucrose gradient at 200,000g for 2.5 hours at 
4°C using a SWT41i rotor (Beckman Brea). Fractions (0.9 mL) were 
collected and 260 nm absorbance monitored by spectrophotometry. 
RNA from each fraction was used for qPCR.
Protein extraction and Western blot analysis. Fifty micrograms 
protein was resolved by SDS-PAGE and transferred to PVDF mem-
brane. In all analyses, equal loading was verified using anti-actin or 
anti-GAPDH antibody. Antibodies and conditions used for Western 
blot are listed in Supplemental Table 7.
A1CF-RNA coimmunoprecipitation. A1CF-RNA coimmunoprecip-
itation was performed as previously described (11). Freshly harvest-
ed, minced livers were exposed to 300 mJ/cm2 UV irradiation in a 
Stratalinker 1800 (Stratagene), collected in 1× PBS, and resuspended 
into PLB buffer (10 mM HEPES [pH 8], 100 mM KCl, 5 mM MgCl2, 
10 mM ribonucleoside vanadyl complexes [Sigma-Aldrich], 0.5% 
Nonidet P-40, 1 mM DTT, 0.2 mM PMSF, and protease inhibitors). 
Cleared lysates were incubated with 0.1 mL of pre-swollen magnetic 
& Instrumentation) and Nuance 2.10 software. Images were acquired 
at 20 nm wavelength intervals and combined into 1 image. A spectral 
library was created and served as reference with individual fluores-
cent signals corresponding to total A1CF, nuclear A1CF, counterstain 
(hematoxylin), and autofluorescence. Autofluorescence was subtract-
ed from the spectral reference. Two ×20 magnification fields per sam-
ple were randomly analyzed. The emission spectra for total and nuclear 
A1CF were acquired and saved as an image cube that contained both 
individual signal components, which were then unmixed and analyzed 
separately. The intensity of staining was defined by pixels evaluated in 
the analyzed area, including the entire field for total A1CF staining and 
all nuclei for nuclear staining. Total pixel values for total and nuclear 
A1CF represent the mean of 2 measurements per sample. Stained area 
was expressed as a percentage of total area. Unstained samples were 
evaluated using the same parameters used to create the spectral refer-
ence (fluorescent signals for both total and nuclear A1CF, counterstain, 
and autofluorescence). These samples showed only counterstaining 
background. Samples were considered positively stained when the 
total pixel value was above counterstain background.
Studies in primary hepatocytes. Livers were perfused and digested 
with 0.05% collagenase (Type IV, C5138, Sigma-Aldrich), and hepato-
cytes were plated on collagen-coated dishes overnight. APOB synthesis 
and secretion were studied as previously described (54), with 35S-methi-
onine pulsed for 30 minutes and chased for 0, 2, and 4 hours. Aliquots 
of cell lysate and medium were immunoprecipitated with APOB IgG and 
separated by 4%–15% gradient SDS-PAGE. The data were normalized to 
total TCA-precipitable radioactivity. CRISPR-targeted HepG2 cells were 
generated as previously described (17).
RNA extraction and RNA-Seq. For each genotype and condition, 
3 pools were prepared, each containing RNAs from 3–4 separate 
mice, for a total of 10 mg RNA per final pool. Pools were subjected to 
Figure 12. Summary of differentially expressed genes in liver of 12-month-old chow-fed A1cf+/Tg mice. (A) Heatmap showing expression of 1505 differ-
entially expressed genes in A1cf+/Tg liver. (B) Gene Ontology analysis depicting functional categories overrepresented (red) and underrepresented (blue) in 
A1cf+/Tg livers. (C) Venn diagram summarizing comparative analysis between 1505 differentially altered genes in A1cf+/Tg liver and A1CF RNA targets iden-
tified by RNA CLIP. Six A1CF RNA targets showed altered expression, with 4 (Spag5, Abcc12, Phlda2, and Cdh1) upregulated (red) and 2 (Dmrta1 and Irx1) 
downregulated (blue). Expression was confirmed by qPCR (6–8 animals per genotype). Data indicate mean ± SEM, *P < 0.01, **P < 0.05 (unpaired t test).
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mM DTT, 1× protease inhibitors, 2 mM Na3VO4, 5 mM sodium pyro-
phosphate, and RNasin (Promega), incubated on ice, and frozen at 
–80°C. Cells were homogenized, and cleared lysates were treated 
with RQ1 DNase (Promega) for 5 minutes at 37°C followed by 15 
minutes of incubation at room temperature with RNase T1 (Fer-
mentas). A1CF-RNA complexes were immunoprecipitated and 
treated on-beads with RNase T1, ligated with RNA adapters (RL5a-
TYE705 and RL3-biotin), resolved on SDS-PAGE, and transferred 
to nitrocellulose. The RNP complexes were excised and treated 
with Proteinase K (Thermo Scientific). Phenol/chloroform-puri-
fied RNA was subjected to cDNA synthesis using DP3 primer, fol-
lowed by PCR using DP5a and DP3 primers. PCR conditions were 
as follows: 94°C for 2 minutes; 40 cycles at 94°C for 30 seconds, 
58°C for 30 seconds, 68°C for 30 seconds; 68°C for 10 minutes. 
PCR products were gel-purified and subjected to a second round of 
amplification using DSFP5a and indexed DSFP3 primer (RPIX-D3) 
(1 per template) with the following conditions: 94°C for 2 minutes; 
35 cycles at 94°C for 30 seconds, 62°C for 45 seconds, 68°C for 
45 seconds; and 68°C for 10 minutes. Final PCR products were 
gel-purified and submitted for high-throughput sequencing using 
primer SSP1. Primer sequences were as follows: RL5a-TYE705: 
5′-AGGGAGGACGAUGCGG-3′; RL3-biotin: 5′-GGCGACCUU-





CGCTGGAAGTGACTGACAC-3′. The underlined 6-nucleotide 
sequence represents the index. Each index is as follows: RPIX2-
DP3: ACATCG; RPIX3-DP3: GCCTAA; RPIX4-DP3: TGGT-
CA; RPIX5-DP3: CACTGT; RPIX6-DP3: ATTGGC; RPIX7-DP3: 
GATCTG; RPIX8-DP3: TCAAGT; RPIX9-DP3: CTGATC; SSP1: 
5′-CTATGGATACTTAGTCAGGGAGGACGATGCGG-3′.
Bioinformatics analysis. Microarray data was processed using the 
R/Bioconductor package limma (51). Background correction was per-
formed using the normexp + offset method (56). The loess and scale 
methods (57) were used for normalization within and between arrays, 
Dynabeads protein A beads (Invitrogen). Aliquots were extracted 
with TRIzol as input RNA. The remainder was incubated overnight, 
with either protein A coupled to anti-A1CF (25 μg), or rabbit IgG in 
NT2 buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM MgCl2, 0.05% 
Nonidet P-40) supplemented with 200 U of RNase inhibitor (Invitro-
gen), 2% ribonucleoside vanadyl complexes, 1 mM DTT, and 150 mM 
EDTA. The beads were washed twice in buffer A (1× PBS [no Mg2+, no 
Ca2+], 0.1% SDS, 0.5% deoxycholate, 0.5% Nonidet P-40), twice in 
buffer B (5× PBS [no Mg2+, no Ca2+], 0.1% SDS, 0.5% deoxycholate, 
0.5% Nonidet P-40), and twice in buffer C (50 mM Tris [pH 7.4],10 
mM MgCl2, 0.5% Nonidet P-40). Beads were incubated 30 minutes 
at 55°C with 30 μg of proteinase K (Sigma-Aldrich) and 0.1% SDS in 
1× NT2 buffer supplemented with 80 U of RNase OUT (Promega). 
The phenol/chloroform-extracted RNA was used for cDNA synthe-
sis followed by PCR using Sox9-specific primers: Fwd825 5′-GAA-
GAGACCCTTCGTGGAGGAGGCGG-3′; Rev1040 5′-TGCACCT-
CACTCATGCCGGAGGAGG-3′. PCR products from A1CF-specific 
immunoprecipitation were gel-purified and sequenced.
RNA CLIP-Seq was performed as previously described (28). 
Primary hepatocytes (108) from 12-week-old A1cf+/Tg mice seeded 
on 10 mm collagen-coated plates were exposed to 400 mJ/cm2 of 
254 nm UV light in a Stratalinker 2400 (Stratagene). Hepatocytes 
were scraped in 1 mL lysis buffer containing 50 mM HEPES (pH 
7.5), 150 mM KCl, 2 mM EDTA, 1 mM NaF, 0.5% (vol/vol) NP40, 1 
Table 3. Distribution of patients by A1CF expression category in 
uninvolved and tumor tissue







Figure 13. Expression profile of 
differentially expressed A1CF RNA 
CLIP targets in 12-month-old A1cf–/– 
mice. Heatmap representation of 298 
genes with altered expression in liver 
of 12-month-old chow-fed A1cf–/– mice. 
Expression of A1CF RNA targets, 
differentially expressed in 12-month-
old A1cf+/Tg, in liver of 12-month-old 
A1cf–/– mice. Genes upregulated in aged 
A1cf+/Tg mice are indicated in red; genes 
downregulated are indicated in blue. 
RNA-Seq analysis showed that of the 
6 genes identified from RNA-Seq and 
RNA CLIP in A1cf+/Tg mice, only Cdh1 
was both upregulated in A1cf+/Tg mice 
and downregulated in A1cf–/– mice. Cdh1 
RNA expression in A1cf+/Tg and A1cf–/– 
liver was confirmed by qPCR (n = 6–7 
per genotype). Data represent mean ± 
SEM, *P < 0.05 (unpaired t test).
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GEO Series accession number GSE157516 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE157516).
Studies with human subjects. Deidentified human liver tissue 
blocks were obtained from the Department of Pathology at Wash-
ington University School of Medicine. For the evaluation of HCC 
samples, a total of 137 patients were analyzed from a patient cohort 
at Mayo Clinic, Rochester, Minnesota. A tissue microarray was 
constructed using 2 uninvolved and 2 tumor tissue samples per 
patient, which were analyzed for A1CF expression by immunohis-
tochemistry. Available clinical and laboratory data are presented in 
Supplemental Table 2. Patients were followed for an average of 3.7 
years after diagnosis. Patients were classified as having NAFLD as 
an underlying component of HCC (a) if confirmed by history and 
pathological examination or (b) if they had a BMI greater than 30 
(>25 for Asians) and there was no other identified etiology (viral hep-
atitis, alcohol, etc.). A1CF expression was defined as total pixels per 
high-power field and categorized as follows: category 1 (less than 12 × 
104 pixels), category 2 (12 × 104 to 23 × 104 pixels), category 3 (23 × 104 
to 32 × 104 pixels), category 4 (greater than 32 × 104 pixels). A second 
set of patient samples was obtained from cirrhotic and normal liver 
tissue in a cohort of patients undergoing surgical resection at Queen 
Mary Hospital, Hong Kong. Demographic data for these subjects are 
shown in Supplemental Table 6.
Statistics. Data are mean ± SEM for the indicated sample num-
ber. Statistical significance was set at a P value less than 0.05. Data 
respectively. RNA-Seq reads were aligned to the Ensembl release 76 
primary assembly with STAR version 2.5.1a (58). Unsupervised hier-
archical clustering of samples was performed with Cluster3 (59), and 
heatmaps were generated with Java TreeView (60). Gene counts were 
derived from the number of uniquely aligned unambiguous reads by 
Subread:featureCount version 1.4.6-p5 (61). Isoform expression of 
known Ensembl transcripts was estimated with Salmon version 0.8.2 
(62). All gene counts were imported into the R/Bioconductor package 
edgeR (63), and TMM normalization size factors were calculated to 
adjust for differences in library size. The TMM size factors and the 
matrix of counts were imported into the R/Bioconductor package 
limma (64). Weighted likelihoods based on the observed mean-vari-
ance relationship of every gene and sample were calculated for all 
samples with voomWithQualityWeights (65). Differential expression 
analysis was performed to analyze for differences between condi-
tions, and the results were filtered only for the genes with Benjami-
ni-Hochberg false discovery rate adjusted P values less than or equal 
to 0.05. The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) tool (66, 67) was used to identify enrichment for 
functional pathways within differentially expressed gene sets.
Data availability. The RNA-Seq and RNA CLIP data discussed 
in this publication were deposited in the NCBI’s Gene Expres-
sion Omnibus and are accessible through GEO Series accession 
number GSE157233 (https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE157233). The RNA array data are accessible through 
Figure 14. A1CF expression inferred from immunohistochemical staining in human HCC tissue microarray. (A) Top: A1CF staining of normal human liver 
showing homogeneous strong nuclear expression. Scale bars: 50 μm. Bottom: A1CF in cirrhotic and HCC tissue. Staining shows a gradient of expression 
with strong nuclear A1CF staining at the edge of cirrhotic nodules and tumor (arrowheads). Scale bars: 50 μm (first 3 panels) and 20 μm (last panel). (B) 
A1CF expression in 137 human samples from a tissue microarray. Samples were categorized according to A1CF staining evaluated by quantitation of pix-
els (see Methods). A representative image of each category is shown. Scale bars: 50 μm. (C) A1CF expression and comparison among fibrosis categories 
in uninvolved and tumor tissues from all patients. Data represent mean ± SEM (unpaired t test). (D) A1CF expression in uninvolved tissue and compar-
ison among patients with low and high levels of AFP, represented as mean ± SEM (unpaired t test). (E) Kaplan-Meier plots of the overall survival rates 
in HCC subjects with underlying NAFLD, stratified by A1CF staining intensity. Patients were divided into 4 quartiles based on A1CF total expression in 
uninvolved tissue. Patients with highest A1CF staining (quartile 4) show significantly reduced survival compared with patients with lower A1CF staining 
intensity (quartiles 1–3). Inset shows Cox proportional hazard values.
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also investigated the prognostic role of tissue A1CF expression in a 
subset of HCC patients with NAFLD (n = 17/19; Supplemental Table 
4). The association between A1CF expression and overall survival 
was also adjusted for recurrence and time to the first recurrence 
in this subgroup. Statistical analysis of clinical data was conducted 
using Stata statistical software version SE 11.2 (StataCorp LP).
Study approval. All animal experiments were conducted in accor-
dance with the guidelines of the Institutional Animal Care and Use 
Committee of Washington University School of Medicine (IACUC 
20180266, 20190028). Collection of samples from the Mayo Clinic 
patient cohort was approved by the Mayo Clinic Institutional Review 
Board (IRB 16-003945). Collection of samples from the Hong Kong 
patient cohort was approved by the Institutional Review Board of the 
University of Hong Kong/Hospital Authority Hong Kong West Cluster. 
For the TMAs, not all the patients provided written informed consent. 
Both patients who provided written informed consent and deceased 
patients who did not opt out of research, as required by Minnesota 
law, have previously been approved by the Mayo Clinic Institutional 
Review Board for inclusion in our Hepatobiliary Neoplasia Biorepos-
itory (IRB 707-03). TMAs were assembled from paraffin blocks from 
these patients stored in the Mayo Pathology Tissue Archives.
were analyzed using GraphPad Prism 7.02 (GraphPad Software Inc.) 
by unpaired t test or Mann-Whitney U test. For multigroup compar-
isons, statistical differences were performed by 1-way ANOVA and 
Tukey’s multiple-comparison post hoc test.
Statistical analyses on the clinical samples were performed 
using the average A1CF expression of paired samples (pixel count 
per high-power field) per tissue type. Unpaired t test or 1-way ANO-
VA was used to compare A1CF expression of tumor or uninvolved 
tissue across subgroups of HCC patients categorized based on dif-
ferent clinical and paraclinical parameters. For survival analysis, we 
used Kaplan-Meier curves to estimate overall survival patterns in 
patients with different levels of A1CF expression. We also used Cox 
proportional hazard modeling to adjust the prognostic role of A1CF 
expression in HCC patients for other putative prognostic factors. 
First, simple Cox models were used to identify factors associated 
with overall survival of patients. Next, we fit the preliminary mul-
tivariable model based on A1CF and other candidate factors iden-
tified from the previous step and used backward elimination meth-
od to reach the final multivariable Cox proportional hazard model. 
Prognostic factors with significant hazard ratios or major contribu-
tion to fitness of the model were retained in the final Cox model. We 
Figure 15. Schematic summary of findings with an integrated mechanism for A1CF-induced hepatic carcinogenesis. Hepatic overexpression of A1CF 
induces steatosis via pathways including increased expression of lipogenic genes, increased fatty acid/lipid uptake (Cidea, Mogat1, Mogat2, Cd36), and 
reduced VLDL APOB secretion. Increased A1CF expression is also associated with increased oxidative stress (Gstm3, Gpx3, Cbr3), augmented inflamma-
tory response (Il19, Cxcl14, Tnfα, Ccr2, Ly6c), and exaggerated extracellular matrix organization (Mmp2, Col1a1, Col4a1, Sparcl1), which together promote 
accumulation of collagen and fibrosis. In parallel, hepatic overexpression of A1CF increases expression of proliferative genes (Mcm2, Mcm4, Mcm6, 
Kif20a), organogenic genes (Bmp7, Sox4, Sox9, Tmprss4), and oncogenic genes (Jak3, Klf4, Tmprss4) and decreases expression of tumor suppressor 
genes (Pbrm1, Rb1, Sall2, Cdh24). These adaptive responses, including steatosis, fibrosis, and augmented proliferation, combine to promote sponta-
neous hepatic carcinogenesis in A1cf+/Tg mice.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 7J Clin Invest. 2021;131(1):e138699 https://doi.org/10.1172/JCI138699
DCR, and JCM); RGC TRS T12-704/16-R (to ION); DK106382 
and CA230282 (to DCR); P50CA210964 (Mayo Clinic Hepa-
tobiliary SPORE) from the National Cancer Institute (to LRR); 
and R01DK105129 and R01DK094989 (to JCM).
Address correspondence to: Nicholas O. Davidson, Gastroen-
terology Division, Washington University School of Medicine, 
Box 8124, 660 S. Euclid Ave., St. Louis, Missouri 63110, USA. 
Phone: 314.362.2027; Email: nod@wustl.edu. JDR’s present 
address is: University of Iowa, Iowa City, Iowa, USA. JHN’s 
present address is: Maine Medical Center Research Institute, 
Scarborough, Maine, USA. YH’s present address is: CHA Bun-
dang Medical Center, CHA University, Gyeonggi-do, South 
Korea. BBM’s present address is: Poseida Therapeutics Inc., 
San Diego, California, USA.
Author contributions
VB and NOD developed study design and approach. VB, JDR, 
EAM, and YX performed experimental methodology and animal 
and cell studies. VB, IN, EMB, JCM, ION, YH, and LRR provid-
ed pathology and immunohistochemical analysis. JDR, VB, JHN, 
SS, BBM, JCM, and DCR performed bioinformatics analysis. VB, 
JDR, JHN, JCM, DCR, IN, YH, LRR, and NOD interpreted the 
data. VB, JDR, SS, JHN, IN, YX, EAM, BBM, EMB, JCM, DCR, 
ION, YH, LRR, and NOD prepared and reviewed the manuscript.
Acknowledgments
This work was supported by grants DK112378 (to DCR and 
NOD); DK119437 (to NOD); P30DK52574 from the Washington 
University Digestive Disease Research Core Center (Advanced 
Imaging and Tissue Analysis Core and Biobank Core) (to NOD, 
 1. Rinella M, Charlton M. The globalization of nonal-
coholic fatty liver disease: prevalence and impact 
on world health. Hepatology. 2016;64(1):19–22.
 2. Forner A, Llovet JM, Bruix J. Hepatocellular carcino-
ma. Lancet. 2012;379(9822):1245–1255.
 3. Adams LA, Anstee QM, Tilg H, Targher G. Non- 
alcoholic fatty liver disease and its relationship with 
cardiovascular disease and other extrahepatic dis-
eases. Gut. 2017;66(6):1138–1153.
 4. Sookoian S, Pirola CJ, Valenti L, Davidson NO. 
Genetic pathways in nonalcoholic fatty liver dis-
ease: insights from systems biology. Hepatology. 
2020;72(1):330–346.
 5. Pirola CJ, Sookoian S. The dual and opposite role 
of the TM6SF2-rs58542926 variant in protecting 
against cardiovascular disease and conferring risk 
for nonalcoholic fatty liver: a meta-analysis. Hepa-
tology. 2015;62(6):1742–1756.
 6. Reyes-Soffer G, et al. Complex effects of inhibiting 
hepatic apolipoprotein B100 synthesis in humans. 
Sci Transl Med. 2016;8(323):323ra312.
 7. Panta R, Dahal K, Kunwar S. Efficacy and safety  
of mipomersen in treatment of dyslipidemia:  
a meta-analysis of randomized controlled trials.  
J Clin Lipidol. 2015;9(2):217–225.
 8. Cuchel M, et al. Efficacy and safety of a microsomal 
triglyceride transfer protein inhibitor in patients 
with homozygous familial hypercholesterolaemia: 
a single-arm, open-label, phase 3 study. Lancet. 
2013;381(9860):40–46.
 9. Lellek H, Kirsten R, Diehl I, Apostel F, Buck F, 
Greeve J. Purification and molecular cloning of a 
novel essential component of the apolipoprotein 
B mRNA editing enzyme-complex. J Biol Chem. 
2000;275(26):19848–19856.
 10. Mehta A, Kinter MT, Sherman NE, Driscoll DM. 
Molecular cloning of apobec-1 complementation 
factor, a novel RNA-binding protein involved in the 
editing of apolipoprotein B mRNA. Mol Cell Biol. 
2000;20(5):1846–1854.
 11. Blanc V, Sessa KJ, Kennedy S, Luo J, Davidson NO. 
Apobec-1 complementation factor modulates liver 
regeneration by post-transcriptional regulation 
of interleukin-6 mRNA stability. J Biol Chem. 
2010;285(25):19184–19192.
 12. Snyder EM, et al. APOBEC1 complementation fac-
tor (A1CF) is dispensable for C-to-U RNA editing in 
vivo. RNA. 2017;23(4):457–465.
 13. Blanc V, et al. Apobec1 complementation factor 
(A1CF) and RBM47 interact in tissue-specific regu-
lation of C to U RNA editing in mouse intestine and 
liver. RNA. 2019;25(1):70–81.
 14. Galloway CA, Ashton J, Sparks JD, Mooney RA, 
Smith HC. Metabolic regulation of APOBEC-1 
complementation factor trafficking in mouse mod-
els of obesity and its positive correlation with the 
expression of ApoB protein in hepatocytes. Biochim 
Biophys Acta. 2010;1802(11):976–985.
 15. Liu DJ, et al. Exome-wide association study of plas-
ma lipids in &gt;300,000 individuals. Nat Genet. 
2017;49(12):1758–1766.
 16. Araki S, Okazaki M, Goto S. Impaired lipid metab-
olism in aged mice as revealed by fasting-induced 
expression of apolipoprotein mRNAs in the 
liver and changes in serum lipids. Gerontology. 
2004;50(4):206–215.
 17. Wen Y, et al. A stable but reversible integrated sur-
rogate reporter for assaying CRISPR/Cas9-stim-
ulated homology-directed repair. J Biol Chem. 
2017;292(15):6148–6162.
 18. Zhou J, et al. Hepatic fatty acid transporter 
Cd36 is a common target of LXR, PXR, and 
PPARγ in promoting steatosis. Gastroenterology. 
2008;134(2):556–567.
 19. Zhou L, et al. Cidea promotes hepatic steato-
sis by sensing dietary fatty acids. Hepatology. 
2012;56(1):95–107.
 20. Lee YJ, et al. Nuclear receptor PPARγ-regulated 
monoacylglycerol O-acyltransferase 1 (MGAT1) 
expression is responsible for the lipid accumulation 
in diet-induced hepatic steatosis. Proc Natl Acad Sci 
U S A. 2012;109(34):13656–13661.
 21. Yamanaka S, et al. Apolipoprotein B mRNA-editing 
protein induces hepatocellular carcinoma and dys-
plasia in transgenic animals. Proc Natl Acad Sci  
U S A. 1995;92(18):8483–8487.
 22. Yamanaka S, Poksay KS, Arnold KS, Innerarity TL. 
A novel translational repressor mRNA is edited 
extensively in livers containing tumors caused by 
the transgene expression of the apoB mRNA- 
editing enzyme. Genes Dev. 1997;11(3):321–333.
 23. Nikolaou KC, Vatandaslar H, Meyer C, Schmid 
MW, Tuschl T, Stoffel M. The RNA-binding pro-
tein A1CF regulates hepatic fructose and glycerol 
metabolism via alternative RNA splicing. Cell Rep. 
2019;29(2):283–300.
 24. Li X, et al. A splicing switch from ketohexokinase-C 
to ketohexokinase-A drives hepatocellular carcino-
ma formation. Nat Cell Biol. 2016;18(5):561–571.
 25. Monga SP. β-Catenin signaling and roles in liver 
homeostasis, injury, and tumorigenesis. Gastroen-
terology. 2015;148(7):1294–1310.
 26. Xu Q, et al. Targeting Stat3 blocks both HIF-1 
and VEGF expression induced by multiple 
oncogenic growth signaling pathways. Oncogene. 
2005;24(36):5552–5560.
 27. Szklarczyk D, et al. STRING v11: protein-protein 
association networks with increased coverage, 
supporting functional discovery in genome-
wide experimental datasets. Nucleic Acids Res. 
2019;47(D1):D607–D613.
 28. Madison BB, et al. LIN28B promotes growth and 
tumorigenesis of the intestinal epithelium via Let-7. 
Genes Dev. 2013;27(20):2233–2245.
 29. Lee AK, Ahn SG, Yoon JH, Kim SA. Sox4 stimulates 
β-catenin activity through induction of CK2. Oncol 
Rep. 2011;25(2):559–565.
 30. Jiao Y, et al. SRY-Box containing gene 4 promotes 
liver steatosis by upregulation of SREBP-1c. Diabe-
tes. 2018;67(11):2227–2238.
 31. Vervoort SJ, van Boxtel R, Coffer PJ. The role 
of SRY-related HMG box transcription factor 4 
(SOX4) in tumorigenesis and metastasis: friend or 
foe? Oncogene. 2013;32(29):3397–3409.
 32. Lourenco AR, Coffer PJ. SOX4: joining the master 
regulators of epithelial-to-mesenchymal transition? 
Trends Cancer. 2017;3(8):571–582.
 33. Li T, Liu X, Yang A, Fu W, Yin F, Zeng X. Asso-
ciations of tumor suppressor SPARCL1 with 
cancer progression and prognosis. Oncol Lett. 
2017;14(3):2603–2610.
 34. Tsukamoto S, et al. Smad9 is a new type of  
transcriptional regulator in bone morphogenetic 
protein signaling. Sci Rep. 2014;4:7596.
 35. Pagadala M, Kasumov T, McCullough AJ, Zein 
NN, Kirwan JP. Role of ceramides in nonalcohol-
ic fatty liver disease. Trends Endocrinol Metab. 
2012;23(8):365–371.
 36. Esmaeili M, Mirzaahmadi S, Tehrani GA. Evalua-
tion of additional Abcc12 gene expression character 
in breast cancer samples using formal diagnostic 
profile. Gene Cell Tissue. 2019;5(4):e84392.
 37. Dominguez D, et al. Sequence, structure, and con-
text preferences of human RNA binding proteins. 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 8 J Clin Invest. 2021;131(1):e138699 https://doi.org/10.1172/JCI138699
Mol Cell. 2018;70(5):854–867.
 38. Sookoian S, Pirola CJ. Genetics of nonalcoholic fatty 
liver disease: from pathogenesis to therapeutics. 
Semin Liver Dis. 2019;39(2):124–140.
 39. de Vries PS, et al. Multiancestry genome-wide 
association study of lipid levels incorporating 
gene-alcohol interactions. Am J Epidemiol. 
2019;188(6):1033–1054.
 40. Blanc V, Kennedy S, Davidson NO. A novel nucle-
ar localization signal in the auxiliary domain of 
apobec-1 complementation factor regulates nucle-
ocytoplasmic import and shuttling. J Biol Chem. 
2003;278(42):41198–41204.
 41. Grohmann M, et al. Obesity drives STAT-1- 
dependent NASH and STAT-3-dependent HCC. 
Cell. 2018;175(5):1289–1306.
 42. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ. 
E-cadherin’s dark side: possible role in tumor pro-
gression. Biochim Biophys Acta. 2012;1826(1):23–31.
 43. Matsumura T, Makino R, Mitamura K. Frequent 
down-regulation of E-cadherin by genetic and 
epigenetic changes in the malignant progression 
of hepatocellular carcinomas. Clin Cancer Res. 
2001;7(3):594–599.
 44. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tio-
llais P, Buendia MA. Altered expression of E-cad-
herin in hepatocellular carcinoma: correlations 
with genetic alterations, β-catenin expression, and 
clinical features. Hepatology. 2002;36(3):692–701.
 45. Ghafoory S, et al. Nuclear accumulation of CDH1 
mRNA in hepatocellular carcinoma cells.  
Oncogenesis. 2015;4:e152.
 46. Liu H, et al. SPAG5 promotes hepatocellular car-
cinoma progression by downregulating SCARA5 
through modifying β-catenin degradation. J Exp 
Clin Cancer Res. 2018;37(1):229.
 47. Sang X, et al. Human hepatic cancer stem cells 
(HCSCs) markers correlated with immune infil-
trates reveal prognostic significance of hepatocellu-
lar carcinoma. Front Genet. 2020;11:112.
 48. Blanc V, Henderson JO, Newberry EP, Kennedy 
S, Luo J, Davidson NO. Targeted deletion of the 
murine apobec-1 complementation factor (acf) 
gene results in embryonic lethality. Mol Cell Biol. 
2005;25(16):7260–7269.
 49. Yang JD, et al. Factors that affect risk for hepatocel-
lular carcinoma and effects of surveillance. Clin 
Gastroenterol Hepatol. 2011;9(7):617–623.
 50. Vilar-Gomez E, et al. Fibrosis severity as a deter-
minant of cause-specific mortality in patients 
with advanced nonalcoholic fatty liver disease: 
a multi-national cohort study. Gastroenterology. 
2018;155(2):443–457.
 51. Wobser H, et al. Lipid accumulation in hepatocytes 
induces fibrogenic activation of hepatic stellate 
cells. Cell Res. 2009;19(8):996–1005.
 52. Hirano K, et al. Targeted disruption of the mouse 
apobec-1 gene abolishes apolipoprotein B mRNA 
editing and eliminates apolipoprotein B48. J Biol 
Chem. 1996;271(17):9887–9890.
 53. Simonet WS, Bucay N, Lauer SJ, Taylor JM. A 
far-downstream hepatocyte-specific control region 
directs expression of the linked human apolipopro-
tein E and C-I genes in transgenic mice. J Biol Chem. 
1993;268(11):8221–8229.
 54. Xie Y, Nassir F, Luo J, Buhman K, Davidson NO. 
Intestinal lipoprotein assembly in apobec-1–/– 
mice reveals subtle alterations in triglyceride 
secretion coupled with a shift to larger lipopro-
teins. Am J Physiol Gastrointest Liver Physiol. 
2003;285(4):G735–G746.
 55. Blanc V, et al. Genome-wide identification and 
functional analysis of Apobec-1-mediated C-to-U 
RNA editing in mouse small intestine and liver. 
Genome Biol. 2014;15(6):R79.
 56. Ritchie ME, et al. A comparison of background 
correction methods for two-colour microarrays. 
Bioinformatics. 2007;23(20):2700–2707.
 57. Smyth GK, Speed T. Normalization of cDNA 
microarray data. Methods. 2003;31(4):265–273.
 58. Dobin A, et al. STAR: ultrafast universal RNA-seq 
aligner. Bioinformatics. 2013;29(1):15–21.
 59. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open 
source clustering software. Bioinformatics. 
2004;20(9):1453–1454.
 60. Saldanha AJ. Java Treeview — extensible visu-
alization of microarray data. Bioinformatics. 
2004;20(17):3246–3248.
 61. Liao Y, Smyth GK, Shi W. featureCounts: an 
efficient general purpose program for assigning 
sequence reads to genomic features. Bioinformatics. 
2014;30(7):923–930.
 62. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford 
C. Salmon provides fast and bias-aware quan-
tification of transcript expression. Nat Methods. 
2017;14(4):417–419.
 63. Robinson MD, McCarthy DJ, Smyth GK. edgeR:  
a Bioconductor package for differential expression 
analysis of digital gene expression data. Bioinfor-
matics. 2010;26(1):139–140.
 64. Ritchie ME, et al. limma powers differential expres-
sion analyses for RNA-sequencing and microarray 
studies. Nucleic Acids Res. 2015;43(7):e47.
 65. Liu R, et al. Why weight? Modelling sample 
and observational level variability improves 
power in RNA-seq analyses. Nucleic Acids Res. 
2015;43(15):e97.
 66. Huang da W, Sherman BT, Lempicki RA. System-
atic and integrative analysis of large gene lists 
using DAVID bioinformatics resources. Nat Protoc. 
2009;4(1):44–57.
 67. Huang da W, et al. Extracting biological meaning 
from large gene lists with DAVID. Curr Protoc Bioin-
formatics. 2009;Chapter 13:Unit 13 11.
